The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem

Simple item page
dc.contributor.authorSecher, Thomasen_ZA
dc.contributor.authorFas, Stefanieen_ZA
dc.contributor.authorFauconnier, Louisen_ZA
dc.contributor.authorMathieu, Mariekeen_ZA
dc.contributor.authorRutschi, Oliveren_ZA
dc.contributor.authorRyffel, Bernharden_ZA
dc.contributor.authorRudolf, Michaelen_ZA
dc.date.accessioned2016-01-02T05:05:48Z
dc.date.available2016-01-02T05:05:48Z
dc.date.issued2013en_ZA
dc.description.abstractPseudomonas aeruginosa ( P. aeruginosa ) infections are associated with considerable morbidity and mortality in immunocompromised patients due to antibiotic resistance. Therefore, we investigated the efficacy of the anti- P. aeruginosa serotype O11 lipopolysaccharide monoclonal antibody Panobacumab in a clinically relevant murine model of neutropenia induced by cyclophosphamide and in combination with meropenem in susceptible and meropenem resistant P. aeruginosa induced pneumonia. We observed that P. aeruginosa induced pneumonia was dramatically increased in neutropenic mice compared to immunocompetent mice. First, Panobacumab significantly reduced lung inflammation and enhanced bacterial clearance from the lung of neutropenic host. Secondly, combination of Panobacumab and meropenem had an additive effect. Third, Panobacumab retained activity on a meropenem resistant P. aeruginosa strain. In conclusion, the present data established that Panobacumab contributes to the clearance of P. aeruginosa in neutropenic hosts as well as in combination with antibiotics in immunocompetent hosts. This suggests beneficial effects of co-treatment even in immunocompromised individuals, suffering most of the morbidity and mortality of P. aeruginosa infections.en_ZA
dc.identifier.apacitationSecher, T., Fas, S., Fauconnier, L., Mathieu, M., Rutschi, O., Ryffel, B., & Rudolf, M. (2013). The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. <i>PLoS One</i>, http://hdl.handle.net/11427/16163en_ZA
dc.identifier.chicagocitationSecher, Thomas, Stefanie Fas, Louis Fauconnier, Marieke Mathieu, Oliver Rutschi, Bernhard Ryffel, and Michael Rudolf "The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem." <i>PLoS One</i> (2013) http://hdl.handle.net/11427/16163en_ZA
dc.identifier.citationSecher, T., Fas, S., Fauconnier, L., Mathieu, M., Rutschi, O., Ryffel, B., & Rudolf, M. (2012). The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PloS one, 8(9), e73396. doi:10.1371/journal.pone.0073396en_ZA
dc.identifier.ris TY - Journal Article AU - Secher, Thomas AU - Fas, Stefanie AU - Fauconnier, Louis AU - Mathieu, Marieke AU - Rutschi, Oliver AU - Ryffel, Bernhard AU - Rudolf, Michael AB - Pseudomonas aeruginosa ( P. aeruginosa ) infections are associated with considerable morbidity and mortality in immunocompromised patients due to antibiotic resistance. Therefore, we investigated the efficacy of the anti- P. aeruginosa serotype O11 lipopolysaccharide monoclonal antibody Panobacumab in a clinically relevant murine model of neutropenia induced by cyclophosphamide and in combination with meropenem in susceptible and meropenem resistant P. aeruginosa induced pneumonia. We observed that P. aeruginosa induced pneumonia was dramatically increased in neutropenic mice compared to immunocompetent mice. First, Panobacumab significantly reduced lung inflammation and enhanced bacterial clearance from the lung of neutropenic host. Secondly, combination of Panobacumab and meropenem had an additive effect. Third, Panobacumab retained activity on a meropenem resistant P. aeruginosa strain. In conclusion, the present data established that Panobacumab contributes to the clearance of P. aeruginosa in neutropenic hosts as well as in combination with antibiotics in immunocompetent hosts. This suggests beneficial effects of co-treatment even in immunocompromised individuals, suffering most of the morbidity and mortality of P. aeruginosa infections. DA - 2013 DB - OpenUCT DO - 10.1371/journal.pone.0073396 DP - University of Cape Town J1 - PLoS One LK - https://open.uct.ac.za PB - University of Cape Town PY - 2013 T1 - The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem TI - The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem UR - http://hdl.handle.net/11427/16163 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/16163
dc.identifier.urihttp://dx.doi.org/10.1371/journal.pone.0073396
dc.identifier.vancouvercitationSecher T, Fas S, Fauconnier L, Mathieu M, Rutschi O, Ryffel B, et al. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PLoS One. 2013; http://hdl.handle.net/11427/16163.en_ZA
dc.language.isoengen_ZA
dc.publisherPublic Library of Scienceen_ZA
dc.publisher.departmentInstitute of Infectious Disease and Molecular Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_ZA
dc.rights.holder© 2013 Secher et alen_ZA
dc.rights.urihttp://creativecommons.org/licenses/by/4.0en_ZA
dc.sourcePLoS Oneen_ZA
dc.source.urihttp://journals.plos.org/plosoneen_ZA
dc.subject.otherPseudomonas aeruginosaen_ZA
dc.subject.otherPneumoniaen_ZA
dc.subject.otherMouse modelsen_ZA
dc.subject.otherAntibioticsen_ZA
dc.subject.otherAntibiotic resistanceen_ZA
dc.subject.otherInflammationen_ZA
dc.subject.otherNeutropeniaen_ZA
dc.subject.otherNeutrophilsen_ZA
dc.titleThe anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenemen_ZA
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Secher_Anti_Pseudomonas_aeruginosa_Antibody_2013.pdf
Size:
1.65 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles